TP53 and neoplasm: A parallel experiment comparing p53-KO and R172H tumors demonstrated greater aggressiveness of the p53-KO xenografts (median survival: 32 vs. 82 days), but both tumor types responded similarly to Avelumab (Fig. S4A).